Tango Therapeutics, Inc. (TNGX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.
Tango Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 107 | $2,132.69 | $2,490.96 | $358.27 | 16.8% |
 Farallon Capital Farallon Capital Management LLC | 12.28M | $157.48M | $275.13M | $117.65M | 74.71% |
| NA Nizar Araji National Bank Of Canada /FI/ | 24 | $781.44 | $558.72 | -$222.72 | -28.5% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 210 | $5,239.5 | $5,865.3 | $625.8 | 11.94% |
| BG Bart Gancher Intech Investment Management LLC | 31,493 | $163,308.36 | $847,319.16 | $684,010.8 | 418.85% |
Tango Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AY Alethia Young Cantor Fitzgerald | 349.02 | $7,692.31 | $8,226.3 | $533.99 | 6.94% |
Tango Therapeutics, Inc. (TNGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tango Therapeutics, Inc. ever had a stock split?
Tango Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Malte Peters CEO | NASDAQ (NMS) Exchange | 87583X109 CUSIP |
| US Country | 137 Employees | - Last Dividend | - Last Split | 3 Sep 2020 IPO Date |
Overview
Tango Therapeutics, Inc. is a pioneering biotechnology firm engaged in the discovery and development of novel cancer treatments. With its foundation laid in 2017 and headquartered in Cambridge, Massachusetts, Tango's mission revolves around crafting innovative therapeutic strategies to tackle various cancer types. The company's robust research and development activities are highlighted by its strategic collaboration with Gilead Sciences, Inc., focusing on the discovery, development, and commercialization of a new pipeline of cancer therapies. This partnership underscores Tango Therapeutics' commitment to advancing the landscape of cancer treatment through cutting-edge scientific innovation and collaboration.
Products and Services
- TNG908
- Ubiquitin-specific protease 1 (USP1) inhibitor
- Target 3 inhibitor for STK11-mutant cancers
The flagship program of Tango Therapeutics, TNG908, stands as a testament to the company's innovative approach in cancer therapy. It is a synthetic lethal small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5). This drug candidate is primarily developed for treating cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. By inhibiting PRMT5, TNG908 disrupts the cancer cell's abnormal growth mechanisms, offering a novel approach to cancer treatment.
This therapeutic candidate marks another stride in Tango's commitment to addressing genetically defined cancers. The USP1 inhibitor is designed to treat patients harboring BRCA1 or BRCA2 mutations. These genetic alterations are commonly associated with a higher risk of developing several cancer types, including breast and ovarian cancer. By targeting USP1, Tango aims to exploit a critical vulnerability in cancer cells with these mutations, showcasing the potential for precision medicine in cancer care.
Further expanding its portfolio, Tango is developing a therapeutic product aimed at combating STK11-mutant cancers. Although specific details about this program are not disclosed, the focus on STK11 mutations—which are prevalent in certain lung cancers—illustrates Tango's commitment to targeting genetic drivers of cancer progression. This approach not only highlights the company's innovative edge but also its dedication to addressing unmet medical needs across various cancer patient populations.
Contact Information
